Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
08:00am, Tuesday, 14'th Apr 2026
BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation ae
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest
01:29am, Tuesday, 14'th Apr 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totaling 7,193,959 shares, a drop of 33.6% f
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
12:00pm, Friday, 10'th Apr 2026
Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
11:55am, Friday, 10'th Apr 2026
Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
11:51am, Friday, 10'th Apr 2026
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
10:46am, Friday, 10'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
08:00am, Thursday, 09'th Apr 2026
BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL
Amneal to Report First Quarter 2026 Results on May 1, 2026
04:01pm, Tuesday, 07'th Apr 2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month
08:00am, Tuesday, 07'th Apr 2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Target Price from Analysts
01:25am, Tuesday, 07'th Apr 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has earned a consensus recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat.com reports. One resear
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by SG Americas Securities LLC
05:25am, Monday, 30'th Mar 2026
SG Americas Securities LLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) by 2,866.0% in the undefined quarter, according to the company in its most recent disclosure wi
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
12:11pm, Friday, 20'th Mar 2026
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a po
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy
03:09pm, Monday, 16'th Mar 2026
Amneal Pharmaceuticals, Inc. remains a Buy, with 45-55% upside potential and a $5-6bn market cap target in my opinion. AMRX delivered strong 2025 results—revenue up to $3.02bn, operating income $421
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:40pm, Tuesday, 10'th Mar 2026
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
New Strong Buy Stocks for March 9th
09:26am, Monday, 09'th Mar 2026
ECG, AMRX, NESR, ACMR and HSY have been added to the Zacks Rank #1 (Strong Buy) List on March 9th, 2026.
